Teleflex Incorporated (NYSE:TFX) VP John Deren sold 1,347 shares of the company’s stock in a transaction on Tuesday, June 12th. The stock was sold at an average price of $284.57, for a total value of $383,315.79. Following the transaction, the vice president now directly owns 1,419 shares in the company, valued at $403,804.83. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Shares of NYSE TFX traded up $0.18 during mid-day trading on Thursday, hitting $284.44. The stock had a trading volume of 7,651 shares, compared to its average volume of 302,948. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.18 and a quick ratio of 1.45. Teleflex Incorporated has a twelve month low of $197.72 and a twelve month high of $288.78. The company has a market cap of $12.93 billion, a price-to-earnings ratio of 33.73, a PEG ratio of 1.99 and a beta of 1.19.
Teleflex (NYSE:TFX) last released its earnings results on Thursday, May 3rd. The medical technology company reported $2.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.94 by $0.21. Teleflex had a return on equity of 16.60% and a net margin of 7.51%. The firm had revenue of $587.23 million for the quarter, compared to the consensus estimate of $568.29 million. During the same period in the prior year, the firm earned $1.80 EPS. The firm’s revenue was up 20.4% on a year-over-year basis. research analysts expect that Teleflex Incorporated will post 9.83 earnings per share for the current year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. State Treasurer State of Michigan increased its position in shares of Teleflex by 1.2% in the 1st quarter. State Treasurer State of Michigan now owns 16,430 shares of the medical technology company’s stock valued at $4,189,000 after acquiring an additional 200 shares during the period. Osterweis Capital Management Inc. increased its position in shares of Teleflex by 0.3% in the 4th quarter. Osterweis Capital Management Inc. now owns 90,707 shares of the medical technology company’s stock valued at $22,570,000 after acquiring an additional 242 shares during the period. CIBC Asset Management Inc increased its position in shares of Teleflex by 12.9% in the 1st quarter. CIBC Asset Management Inc now owns 2,172 shares of the medical technology company’s stock valued at $554,000 after acquiring an additional 249 shares during the period. Barometer Capital Management Inc. increased its position in shares of Teleflex by 3.2% in the 4th quarter. Barometer Capital Management Inc. now owns 8,075 shares of the medical technology company’s stock valued at $2,009,000 after acquiring an additional 250 shares during the period. Finally, Ranger Investment Management L.P. increased its position in shares of Teleflex by 28.2% in the 4th quarter. Ranger Investment Management L.P. now owns 1,217 shares of the medical technology company’s stock valued at $303,000 after acquiring an additional 268 shares during the period. 89.96% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities analysts have recently issued reports on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $293.00 price target (up from $285.00) on shares of Teleflex in a research report on Thursday, May 3rd. Leerink Swann upped their price target on Teleflex from $309.00 to $317.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 5th. Deutsche Bank set a $255.00 price target on Teleflex and gave the stock a “hold” rating in a research report on Friday, May 4th. Goldman Sachs Group assumed coverage on Teleflex in a research report on Wednesday, April 4th. They set a “neutral” rating and a $257.00 price target on the stock. Finally, ValuEngine downgraded Teleflex from a “buy” rating to a “hold” rating in a research report on Wednesday, March 7th. One analyst has rated the stock with a sell rating, six have given a hold rating and six have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $282.50.
Teleflex Company Profile
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.